One of the missions of NewG Lab Pharma
(NGLP) will be to develop novel anticancer
therapeutics that extend the life of cancer patients
without compromising the quality of life.
Treated at Frankfurt University in 2009
16yr old patient with progressive fibrolamellar hepatocellular carcinoma, 3 month of prognosis
The patient was given 9 doses of KAT (200 mg) over a period of 6 months
After treatment, the patient loses cancer and the tissue regenerates from 5% to 30%
1.5years after CR, the patient dies of pneumonia due to excessive antibiotic therapy
that destroyed liver function. No cancer was found as a result of CT scan by postmortem examination.
- Left images taken before treatment, right images taken after 9th treatment.
- Tumors throughout liver (L) are necrotic, encapsulated, and showing fibrosis.
- Lymph nodes that were enlarged (green star) have returned to stable size and shape.
- Spleen size (S) that was enlarged has drastically reduced.